Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Deadly Skin Cancer Cases Hit Record High
The number of people diagnosed with the deadliest form of skin cancer has crashed through the 10,000 barrier after an alarming rise in new cases, according to the latest Cancer Research UK figures revealed today.

Sometimes Insurance No Match For Health Costs
Americans with serious illnesses who must often choose between paying a mortgage or their health premiums and deductibles are often going broke, The Seattle Times reports.
News of the day
Common Cancer Drug May Increase Risk Of Deadly GI Perforations
Cancer patients treated with the widely used drug bevacizumab (Avastin) in combination with chemotherapy are at greater risk of life-thereatening gastrointestinal (GI) perforations. This is the conclusion of Shenhong Wu, M.D., Ph.D., Principal Investigator, and colleagues at Stony Brook University Medical Center, in a study published online and in the June print issue of The Lancet Oncology.
Oncology

MDRNA, Inc. Receives Full FDA Approval Of Generic Calcitonin-Salmon Nasal Spray For Osteoporosis

MDRNA, Inc. (NASDAQ: MRNA) announced that it has obtained full U.S. Food and Drug Administration (FDA) approval of its Abbreviated New Drug Application (ANDA) for generic calcitonin-salmon nasal spray for the treatment of osteoporosis and that Par Pharmaceutical Companies, Inc. (NYSE: PAR) has launched the product. Calcitonin-salmon nasal spray, a legacy product developed by MDRNA in the early 2000s, is the generic equivalent of Miacalcin® nasal spray, marketed by Novartis Pharmaceuticals Corporation. U.S. sales of Miacalcin® were approximately $112 million in 2008, according to IMS Health data. On March 31, 2009, MDRNA and Par entered into an agreement under which Par acquired the Company"s Abbreviated New Drug Application (ANDA) for generic calcitonin-salmon nasal spray and the Company"s FDA-approved, cGMP manufacturing facility in Hauppauge, New York, for an upfront cash payment and profit sharing on commercial sales for five years. "We are pleased that generic calcitonin-salmon nasal spray has received full FDA approval and has been launched by Par," stated J. Michael French, President and CEO of MDRNA. "Revenue generated from the sale of calcitonin-salmon by Par will provide us with working capital to help advance our RNAi programs. I thank the team at MDRNA and Par for their superb efforts to bring this product to market." For additional product information, please visit http://www.parpharm.com/products. MDRNA, Inc.


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009